panitumumab
amgen,takeda,aura biosciences
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ', 'panitumumab', 'aura ']
#asco22 oral abstract session panitumumab + folfiri in ras/braf wt mcrc improve study dr. antonio avallone intermittent administration has less ae's and promising in left-sided mcrc 
Independent Medical Affairs Advisor & Research/Patient Advocate. metastatic colon cancer survivor diagnosed 2003 NED since 2006.
FCOI: https://t.co/cRjnIJrYKm